Search hospitals > Kansas > Lawrence

Lawrence Memorial Hospital

Claim this profile
Lawrence, Kansas 66044
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
395 reported clinical trials
23 medical researchers
Photo of Lawrence Memorial Hospital in LawrencePhoto of Lawrence Memorial Hospital in LawrencePhoto of Lawrence Memorial Hospital in Lawrence

Summary

Lawrence Memorial Hospital is a medical facility located in Lawrence, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Lawrence Memorial Hospital is involved with conducting 395 clinical trials across 504 conditions. There are 23 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Jun Zhang, Gary C. Doolittle, and Chao H. Huang.

Area of expertise

1Cancer
Global Leader
Lawrence Memorial Hospital has run 125 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Lawrence Memorial Hospital has run 72 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Lawrence Memorial Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Pancreatic Cancer
Colorectal Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lawrence Memorial Hospital?
Lawrence Memorial Hospital is a medical facility located in Lawrence, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Lawrence Memorial Hospital is involved with conducting 395 clinical trials across 504 conditions. There are 23 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Jun Zhang, Gary C. Doolittle, and Chao H. Huang.
Where is Lawrence Memorial Hospital located?
**Lawrence Memorial Hospital** - **Address:** 325 Maine Street, Lawrence, KS 66044 - **Location:** Approximately 2 miles from downtown Lawrence, near the intersection of Maine Street and 6th Street.
Who should I call to ask about financial aid or insurance network?
**Lawrence Memorial Hospital Financial Assistance** - For financial assistance, including charity care, payment arrangements, and medical assistance programs, please contact our financial counselor at 785-505-5775. - Application forms and further information are available through the financial counselor.
What insurance does Lawrence Memorial Hospital accept?
Lawrence Memorial Hospital accepts Blue Cross and Blue Shield of Kansas (BCBSKS) insurance plans. The hospital participates with most major managed care and governmental health insurance plans in the Northeast, including Medicaid and Medicare. Patients should contact their health insurance company directly to confirm specific plan and benefit coverage, as participation with health plans does not guarantee coverage.
What awards or recognition has Lawrence Memorial Hospital received?
**Lawrence Memorial Hospital, Lawrence, Kansas** - Recognized as one of the 100 Top Hospitals by Truven Health Analytics. - Received a $2 million grant from the Sunderland Foundation for support.